• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Control of T helper 2 cell function & allergic airway inflammation by PKC

sharon sanders

Editor-in-Chief & President
Control of T helper 2 cell function and allergic airway inflammation by PKC
zeta.gif

</NOBR><NOBR>Pilar Martin<SUP> *</SUP></NOBR>, <NOBR>Ricardo Villares<SUP>
dagger.gif
</SUP></NOBR>, <NOBR>Sandra Rodriguez-Mascarenhas<SUP> *</SUP></NOBR>, <NOBR>Angel Zaballos<SUP>
dagger.gif
</SUP></NOBR>, <NOBR>Michael Leitges<SUP>
Dagger.gif
</SUP></NOBR>, <NOBR>Judit Kovac<SUP>
Dagger.gif
</SUP></NOBR>, <NOBR>Irene Sizing<SUP>
sect.gif
</SUP></NOBR>, <NOBR>Paul Rennert<SUP>
sect.gif
</SUP></NOBR>, <NOBR>Gabriel M?rquez<SUP>
dagger.gif
</SUP></NOBR>, <NOBR>Carlos Mart?nez-A<SUP>
dagger.gif
</SUP></NOBR>, <NOBR>Mar?a T. Diaz-Meco<SUP> *</SUP></NOBR>, and <NOBR>Jorge Moscat<SUP> *,</SUP><SUP> ?</SUP></NOBR>

<SUP>*</SUP>Centro de Biolog?a Molecular Severo Ochoa and <SUP>
dagger.gif
</SUP>Departamento de Inmunologia y Oncologia-Centro Nacional de Biotecnolog?a, Consejo Superior de Investigaciones Cientificas, Universidad Autonoma de Madrid, Cantoblanco, 28049 Madrid, Spain; <SUP>
Dagger.gif
</SUP>Max-Planck-Institut f?r Experimentelle Endokrinologie, Feodor-Lynen-Strasse 7, 30625 Hannover, Germany; and <SUP>
sect.gif
</SUP>Biogen, 14 Cambridge Center, Cambridge, MA 02142
Edited by Tak Wah Mak, University of Toronto, Toronto, ON, Canada, and approved May 20, 2005 (received for review February 11, 2005)

<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Abstract [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]Top
dot.gif
Abstract
Materials and Methods
Results
Discussion
References
[/SIZE]</TH></TR></TBODY></TABLE>
Asthma is a disease of chronic airway inflammation in which<SUP> </SUP>T helper (Th) 2 cells play a critical role. The molecular mechanisms<SUP> </SUP>controlling Th2 differentiation and function are of paramount<SUP> </SUP>importance in biology and immunology. PKC
zeta.gif
has been implicated<SUP> </SUP>in the regulation of apoptosis and NF-
kappa.gif
B, as well as in the control<SUP> </SUP>of T-dependent responses, although no defects were detected<SUP> </SUP>in na?ve T cells from PKC
zeta.gif
<SUP>?/?</SUP> mice. Here, we<SUP> </SUP>report that PKC
zeta.gif
is critical for IL-4 signaling and Th2 differentiation.<SUP> </SUP>Thus, PKC
zeta.gif
levels are increased during Th2 differentiation, but<SUP> </SUP>not Th1 differentiation, of CD4<SUP>+</SUP> T cells, and the loss of PKC
zeta.gif
<SUP> </SUP>impairs the secretion of Th2 cytokines in vitro and in vivo,<SUP> </SUP>as well as the nuclear translocation and tyrosine phosphorylation<SUP> </SUP>of Stat6 and Jak1 activation, essential downstream targets of<SUP> </SUP>IL-4 signaling. Moreover, PKC
zeta.gif
<SUP>?/?</SUP> mice display dramatic<SUP> </SUP>inhibition of ovalbumin-induced allergic airway disease, strongly<SUP> </SUP>suggesting that PKC
zeta.gif
can be a therapeutic target in asthma.<SUP> </SUP>

[SIZE=-1]apoptosis | asthma | NF-
kappa.gif
B[/SIZE]
<HR align=center width="50%" noShade SIZE=1>Asthma is a chronic lung inflammatory disease with increased<SUP> </SUP>prevalence in developed countries. The pathology of asthma is<SUP> </SUP>associated with aberrant activation of CD4<SUP>+</SUP> lymphocytes differentiated<SUP> </SUP>along the T helper (Th) 2 lineage (1). Na?ve CD4<SUP>+</SUP> Th cells<SUP> </SUP>can differentiate in response to antigen stimulation into two<SUP> </SUP>distinct subsets of effector cells, Th1 and Th2, which display<SUP> </SUP>distinct cytokine profiles and immune regulatory functions (2).<SUP> </SUP>Th1 cells mainly produce IFN-
gamma.gif
and IL-2 and are essential for<SUP> </SUP>cell-mediated immune responses against intracellular pathogens.<SUP> </SUP>Th2 cells produce a different set of cytokines, including IL-4,<SUP> </SUP>IL-5, IL-10, and IL-13, and are important in the control of<SUP> </SUP>humoral immunity and allergy (3). The signaling pathways controlling<SUP> </SUP>Th2 differentiation and function have been the focus of intense<SUP> </SUP>research because they could help to identify therapeutic targets<SUP> </SUP>for asthma and other allergic pathologies. IL-4 is important<SUP> </SUP>for induction and maintenance of differentiated Th2 cells and<SUP> </SUP>for B cell Ig isotype switching to IgE in mice (4). IL-4 and<SUP> </SUP>IL-13 share interactions with the IL-4R
alpha.gif
chain and activate the<SUP> </SUP>transcription factor Stat6 through a Jak1/Jak3 signaling pathway<SUP> </SUP>(3, 5).<SUP> </SUP>
The role of the different PKC isoforms in lymphocyte activation<SUP> </SUP>and differentiation is a matter of great interest. The recent<SUP> </SUP>generation of mutant mice in which different PKC isotypes have<SUP> </SUP>been genetically inactivated reveals the selective involvement<SUP> </SUP>of each PKC isoform in cell-specific aspects of the immune response<SUP> </SUP>(6). The characterization of knockout mice for the diacylglycerol-insensitive<SUP> </SUP>atypical PKC
zeta.gif
isoform reveals an important role of this kinase<SUP> </SUP>in the immune system (7). Thus, PKC
zeta.gif
<SUP>?/?</SUP> adult mice<SUP> </SUP>are unable to mount an optimal immune response (8), suggesting<SUP> </SUP>alterations in lymphocyte function. Although the humoral response<SUP> </SUP>to a T-independent antigen was reduced in the PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>mice, the major defects were found in mice challenged with a<SUP> </SUP>T-dependent antigen, specifically, in the levels of IgG1, IgG2a,<SUP> </SUP>and IgG2b (8). Also, basal IgE levels were dramatically reduced<SUP> </SUP>in PKC
zeta.gif
<SUP>?/?</SUP> mice compared with WT controls (8), indicating<SUP> </SUP>that some kind of T cell alteration, possibly in the Th2 lineage,<SUP> </SUP>might be produced by the loss of PKC
zeta.gif
. Surprisingly, although<SUP> </SUP>the ability of B cells to proliferate in response to B cell<SUP> </SUP>receptor challenge was reproducibly impaired in the PKC
zeta.gif
-deficient<SUP> </SUP>mice, no major alterations were observed in the proliferation<SUP> </SUP>of na?ve T cells (8). However, the potential role of PKC
zeta.gif
<SUP> </SUP>in Th2 function and asthma had not been addressed previously.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Materials and Methods [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]Top
Abstract
dot.gif
Materials and Methods
Results
Discussion
References
[/SIZE]</TH></TR></TBODY></TABLE>
Mice. PKC
zeta.gif
<SUP>?/?</SUP> and WT mice (SV129J background) are<SUP> </SUP>described in ref. 7. Mice aged between 6 and 8 weeks were used<SUP> </SUP>for the in vitro experiments. Age- and sex-matched 10- to 12-week-old<SUP> </SUP>mice were used for the in vivo asthma model.<SUP> </SUP>
Antibodies and Reagents. Antibodies to murine CD3
epsi.gif
(145-2C11)<SUP> </SUP>and CD28 (37.51) and biotinylated CD8
alpha.gif
(53-6.7), CD11b (Mac-1),<SUP> </SUP>CD16 (2.4G2), CD19 (1D3), CD24 (M1/69), CD62L (MEL-14), CD117<SUP> </SUP>(2B8), B220 (RA3-6B2), and CD4-FITC (L3T4) as well as IL-4-phycoerythrin<SUP> </SUP>(PE) and CD25-PE (PC61) were from Pharmingen. Antibodies to<SUP> </SUP>Stat6 (S-20), phospho-extracellular signal-regulated kinase<SUP> </SUP>(ERK) (E-4), ERK1 (K-23), phospholipase C-
gamma.gif
(Y783), GATA3 (HG3?31),<SUP> </SUP>c-Maf (M-153), actin (I-19), T-bet (4B10), proliferating cell<SUP> </SUP>nuclear antigen (FL-261), and nuclear factor of activated T<SUP> </SUP>cells (NFAT) c1 (7A6) were from Santa Cruz Biotechnology. Stat5,<SUP> </SUP>Jak1, phospho-Stat6 (Tyr-641), phospho-Stat5 (Y694), and phospho-Jak1<SUP> </SUP>(Tyr-1022 and Tyr-1023) antibodies were from Cell Signaling<SUP> </SUP>Technology (Beverly, MA). Recombinant murine IL-2, IL-12, and<SUP> </SUP>IL-4 as well as anti-IFN-
gamma.gif
, anti-IL-5, anti-IL-4R
alpha.gif
, and anti-IL-4<SUP> </SUP>antibodies were from <!--ad-->R & D Systems. IFN-
gamma.gif
, IL-4, IL-5, and<SUP> </SUP>IL-10 ELISA kits were from Pharmingen, and the IL-13 ELISA kit<SUP> </SUP>was from <!--ad-->R & D Systems. Specific polyclonal anti-PKC
zeta.gif
antibody<SUP> </SUP>was generated against the sequence encompassing amino acids<SUP> </SUP>185?244 of PKC
zeta.gif
.<SUP> </SUP>
CD4<SUP>+</SUP> T Cell Isolation and Differentiation. To obtain na?ve<SUP> </SUP>CD4<SUP>+</SUP> T cells, single cell suspensions were prepared from spleens<SUP> </SUP>and mesenteric lymph nodes of the indicated mice and were incubated<SUP> </SUP>with biotinylated antibodies directed at CD8, CD16, CD19, CD24,<SUP> </SUP>CD117, major histocompatibility complex class II (I-A<SUP>b</SUP>), and<SUP> </SUP>CD11b followed by incubation with anti-biotin-conjugated microbeads.<SUP> </SUP>Na?ve CD4<SUP>+</SUP> T cells were negatively selected in an autoMACS<SUP> </SUP>separator (Miltenyi Biotec, Auburn, CA) according to the manufacturer's<SUP> </SUP>instructions. Purified CD4<SUP>+</SUP> T cells were labeled with antibodies<SUP> </SUP>specific for CD4, CD25, CD62L, and B220 and analyzed by flow<SUP> </SUP>cytometry to confirm purity and the na?ve status (Fig.<SUP> </SUP>6, which is published as supporting information on the PNAS<SUP> </SUP>web site). Na?ve CD4<SUP>+</SUP> T cells (10<SUP>6</SUP> cells per ml) were differentiated<SUP> </SUP>in the presence of irradiated antigen-presenting cells (10<SUP>6</SUP><SUP> </SUP>cells per ml), immobilized anti-CD3 (1 ?g/ml), and IL-2<SUP> </SUP>(10 ng/ml). For Th0 cultures, anti IL-4 (4 ?g/ml) and<SUP> </SUP>anti-IFN-
gamma.gif
(4 ?g/ml) were added. For Th1 differentiation,<SUP> </SUP>IL-12 (3.5 ng/ml) and anti-IL-4 (4 ?g/ml) were added to<SUP> </SUP>the culture, whereas IL-4 (4 ng/ml) and anti-IFN-
gamma.gif
(4 ?g/ml)<SUP> </SUP>were added for Th2 differentiation. After 4 days, the cells<SUP> </SUP>were extensively washed, counted, and restimulated as described.<SUP> </SUP>No differences in viability were observed in WT and knockout<SUP> </SUP>na?ve Th0, Th1, or Th2 cells.<SUP> </SUP>
FACS Analysis and Intracellular Staining. GATA3 protein levels<SUP> </SUP>were assessed by intracellular staining in cells fixed overnight<SUP> </SUP>with 70% ethanol at ?20?C and stained with anti-GATA3<SUP> </SUP>or control mouse IgG1 followed by FITC-anti-mouse IgG1. To determine<SUP> </SUP>intracellular IL-4 levels, brefeldin A (BD GolgiPlug, BD Biosciences)<SUP> </SUP>was added 4 h before harvest to Th2 polarized WT and PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>cells that had been restimulated for 48 h with anti-CD3 in the<SUP> </SUP>absence or presence of anti-CD28. Afterward, cells were fixed<SUP> </SUP>and permeabilized by using the BD Cytofix/Cytoperm kit (BD Biosciences)<SUP> </SUP>and stained with anti-IL-4-phycoerythrin. Analysis was performed<SUP> </SUP>in a FACSCalibur cell sorter (BD Biosciences) with [SIZE=-2]CELLQUESTPRO[/SIZE]<SUP> </SUP>software.<SUP> </SUP>
PKC
zeta.gif
Kinase Assay.
Cell extracts prepared in lysis buffer (50<SUP> </SUP>mM Tris?HCl, pH 7.5/150 mM NaCl/1 mM EGTA/2 mM EDTA/1%<SUP> </SUP>Triton X-100) were immunoprecipitated with the specific anti-PKC
zeta.gif
<SUP> </SUP>antibody that does not crossreact with PKC
lambda.gif
/
iota.gif
for2hat4?C.<SUP> </SUP>Immunoprecipitates were captured with protein A and washed extensively<SUP> </SUP>in lysis buffer with 0.5 M NaCl. The enzymatic assay was carried<SUP> </SUP>out in the immunoprecipitates in assay buffer [35 mM Tris?HCl,<SUP> </SUP>pH 7.5/10 mM MgCl<SUB>2</SUB>/100 ?M CaCl<SUB>2</SUB>/0.5 mM EGTA/100 ?M<SUP> </SUP>ATP/5 ?Ci (1 Ci = 37 GBq) of [<SUP>32</SUP>P]ATP] with 4 ?g<SUP> </SUP>of myelin basic protein as substrate for 1 h at 30?C.<SUP> </SUP>
Cytokine Assays. Na?ve CD4<SUP>+</SUP> T cells were stimulated for<SUP> </SUP>72 h with anti-CD3 (10 ?g/ml) plus anti-CD28 (5 ?g/ml),<SUP> </SUP>and Th2-differentiated cells were restimulated for 24 h with<SUP> </SUP>anti-CD3 (10 ?g/ml), after which, supernatants were collected<SUP> </SUP>and cytokine concentrations were measured by ELISA using commercially<SUP> </SUP>available kits. ELISA was also used to determine the levels<SUP> </SUP>of Th2 cytokines in bronchoalveolar lavage (BAL) fluids.<SUP> </SUP>
Immunofluorescent Analysis. Th2 cells (2 [FONT=arial,helvetica]x[/FONT] 10<SUP>5</SUP>) were applied<SUP> </SUP>to glass slides by cytocentrifugation. Cells were fixed, permeabilized<SUP> </SUP>with 0.1% Triton X-100, and incubated with the different antibodies<SUP> </SUP>for 1 h at 37?C and the tetramethylfluorescein tyramide<SUP> </SUP>TSA-Direct amplification system (NEN). For the nuclear staining,<SUP> </SUP>cells were incubated with TO-PRO. Glass coverslips were mounted<SUP> </SUP>on Mowiol and examined with an MRC 1024 confocal system (Bio-Rad)<SUP> </SUP>mounted on an Axiovert 135 microscope (<!--ad-->Zeiss).<SUP> </SUP>
Ovalbumin (OVA)-Induced Allergic Airway Disease. PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>and WT mice (10?12 weeks old) were immunized as described<SUP> </SUP>in ref. 9. Briefly, on day 0, 15 ?g of OVA (Sigma) in<SUP> </SUP>200 ?l of alum (Pierce) were injected i.p. into sensitized<SUP> </SUP>mice. On day 5, the animals received another i.p. injection<SUP> </SUP>of 15 ?g of OVA in 200 ?g of alum and, on day 12,<SUP> </SUP>mice were challenged with aerosolized 0.5% OVA in PBS (two challenges<SUP> </SUP>of 60 min each that were 4 h apart). Control animals were aerosolized<SUP> </SUP>with PBS. On day 14, 40 h after the second OVA challenge, mice<SUP> </SUP>were killed for analysis. For histological analysis, lungs from<SUP> </SUP>PBS- or OVA-treated mice were inflated through the trachea with<SUP> </SUP>50% Jung tissue-freezing medium (Leica, Vienna) in PBS. The<SUP> </SUP>right caudal lobe was trimmed, embedded, frozen, and stored<SUP> </SUP>at ?80?C. For the adoptive transfer experiments, WT<SUP> </SUP>and PKC
zeta.gif
<SUP>?/?</SUP> mice were i.p. injected with 100 ?g<SUP> </SUP>of OVA in 2 mg of alum, and, 5 days later, spleens and mesenteric<SUP> </SUP>lymph nodes were removed for CD4<SUP>+</SUP> T cell isolation and were<SUP> </SUP>cultured for Th2 differentiation for 4 days with irradiated<SUP> </SUP>antigen-presenting cells, OVA (50 ?g/ml), IL-2 (10 ng/ml),<SUP> </SUP>IL-4 (10 ng/ml), and anti-IFN-
gamma.gif
(10 ?g/ml). Afterward,<SUP> </SUP>Th2-like cells were collected, washed, and i.v. injected into<SUP> </SUP>WT and PKC
zeta.gif
<SUP>?/?</SUP> recipient mice, which, 24 h later,<SUP> </SUP>were exposed to inhaled 1% OVA in PBS for a total of 7 days<SUP> </SUP>(4 consecutive days exposed, 2 days rested, and 3 consecutive<SUP> </SUP>days exposed) for 20 min daily. Mice were killed 24 h after<SUP> </SUP>the final exposure to antigen, and histological analysis of<SUP> </SUP>lungs was performed. The appropriate institutional animal use<SUP> </SUP>and care committees approved all animal experiments.<SUP> </SUP>
Statistical Analysis. Statistical analyses were performed by<SUP> </SUP>using Student's t test. P < 0.05 was considered to be significant.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Results [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]Top
Abstract
Materials and Methods
dot.gif
Results
Discussion
References
[/SIZE]</TH></TR></TBODY></TABLE>
Impaired Th2 Differentiation in PKC
zeta.gif
<SUP>?/?</SUP> Mice.
To<SUP> </SUP>determine whether PKC
zeta.gif
may play a role in lineage commitment<SUP> </SUP>of CD4<SUP>+</SUP> T helper cells, we initially differentiated CD4<SUP>+</SUP> T cells,<SUP> </SUP>either WT or PKC
zeta.gif
<SUP>?/?</SUP>, in vitro under Th1 or Th2 polarizing<SUP> </SUP>conditions, after which, cells were stimulated with anti-CD3<SUP> </SUP>antibody for 48 h, and the secretion of IFN-
gamma.gif
and IL-4 was determined<SUP> </SUP>in the Th1 and Th2 cultures, respectively. Results in Fig. 1a<SUP> </SUP>show that whereas IFN-
gamma.gif
secretion is not affected, IL-4 is significantly<SUP> </SUP>reduced in PKC
zeta.gif
<SUP>?/?</SUP> cells (Fig. 1a). The synthesis<SUP> </SUP>of three other Th2 cytokines, IL-5, IL-10, and IL-13, was also<SUP> </SUP>dramatically inhibited in PKC
zeta.gif
<SUP>?/?</SUP> Th2 cells (Fig.<SUP> </SUP>1a). When the levels of intracellular IL-4 were determined in<SUP> </SUP>the presence of brefeldin A by FACS analysis, it was clear that<SUP> </SUP>WT Th2 cells produce significantly more IL-4 than do PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>Th2 cells (Fig. 1b), consistent with the ELISA data in Fig.<SUP> </SUP>1a. Together, these results suggest that PKC
zeta.gif
plays a nonredundant<SUP> </SUP>role in Th2-polarized CD4<SUP>+</SUP> T cells.<SUP> </SUP>
GATA3 expression is a widely established hallmark of the Th2<SUP> </SUP>polarization process (10). Therefore, we initially analyzed<SUP> </SUP>by using flow cytometry the levels of this transcription factor<SUP> </SUP>in CD4<SUP>+</SUP> T cells incubated under Th0, Th1, and Th2 polarizing<SUP> </SUP>conditions. Interestingly, the loss of PKC
zeta.gif
significantly reduces<SUP> </SUP>GATA3 expression in Th2 cells (Fig. 2a), strongly suggesting<SUP> </SUP>that PKC
zeta.gif
plays an important role during Th2 differentiation.<SUP> </SUP>Consistent with this notion, the levels of GATA3, as well as<SUP> </SUP>the levels of Stat6, c-Maf, RelA, and NFATc1, were dramatically<SUP> </SUP>reduced in PKC
zeta.gif
-deficient Th2 cells as determined by immunoblotting<SUP> </SUP>(Fig. 2b). Interestingly, when Th2-polarized T cells were rechallenged<SUP> </SUP>with anti-CD3 plus anti-CD28, the nuclear levels of all of the<SUP> </SUP>transcription factors tested were likewise inhibited in the<SUP> </SUP>PKC
zeta.gif
<SUP>?/?</SUP> cells (Fig. 2c). Therefore, it seems that<SUP> </SUP>PKC
zeta.gif
is required for the Th2 differentiation process to properly<SUP> </SUP>occur and for Th2-polarized cells to respond to an anti-CD3<SUP> </SUP>rechallenge.<SUP> </SUP>
Signaling Cascades Inhibited in PKC
zeta.gif
<SUP>?/?</SUP> T Cells Induced<SUP> </SUP>to Differentiate Along the Th2 Pathway.
Because PKC
zeta.gif
appears<SUP> </SUP>to be important for Th2 polarization, we next sought to determine<SUP> </SUP>whether this kinase is induced during this important differentiation<SUP> </SUP>process. First, we generated a polyclonal antibody that selectively<SUP> </SUP>recognizes PKC
zeta.gif
and that does not crossreact with PKC
lambda.gif
/
iota.gif
. The result<SUP> </SUP>in Fig. 3a shows the specificity of this antibody in immunoblot<SUP> </SUP>analysis of lung extracts, a tissue particularly rich in PKC
zeta.gif
<SUP> </SUP>(7), from WT and PKC
zeta.gif
<SUP>?/?</SUP> mice. Immunoblotting with<SUP> </SUP>an anti-PKC
lambda.gif
/
iota.gif
-specific antibody of the same extracts reveals<SUP> </SUP>that the levels of this aPKC isoform were not affected by the<SUP> </SUP>loss of PKC
zeta.gif
(Fig. 3a). Therefore, we next prepared extracts<SUP> </SUP>from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 conditions,<SUP> </SUP>and the expression of PKC
zeta.gif
was determined by immunoblotting with<SUP> </SUP>our selective antibody. The data in Fig. 3b demonstrate that<SUP> </SUP>PKC
zeta.gif
levels are increased under Th2 polarizing conditions, but<SUP> </SUP>not under Th1 polarizing conditions. Immunoblotting with anti-GATA3<SUP> </SUP>and anti-T-bet demonstrated that cells were properly polarized<SUP> </SUP>to the Th2 and Th1 lineages, respectively (Fig. 3b). To determine<SUP> </SUP>whether this induced PKC
zeta.gif
is enzymatically active, we immunoprecipitated<SUP> </SUP>this kinase from polarized CD4<SUP>+</SUP> T cell extracts, and the enzymatic<SUP> </SUP>activity was determined in a standard kinase assay. The data<SUP> </SUP>in Fig. 3b show that the activity of PKC
zeta.gif
is pronouncedly induced<SUP> </SUP>in Th2 cells.<SUP> </SUP>
<SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (24K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 1. Role of PKC
zeta.gif
in Th2 differentiation and cytokine synthesis. (a) Secretion of IFN-
gamma.gif
in Th1 cells or IL-5, IL-4, IL-13, and IL-10 in Th2 cells in WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice stimulated with anti-CD3 was determined by ELISA. (b) IL-4 intracellular staining of Th2 cells in WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice either untreated or treated with anti-CD3 alone or in combination with anti-CD28. Inset numbers represent the percentage of IL-4-positive cells. The results in a are the mean ? SD of three independent experiments with incubations in triplicate. The results in b are representative of another two experiments. ***, P < 0.001.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (40K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 2. Th2 transcription factors in PKC
zeta.gif
<SUP>?/?</SUP> cells. (a) Intracellular staining of GATA3 in Th0, Th1, and Th2 cells in WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice. The solid line represents GATA3 staining; the dashed line corresponds to the mouse IgG1 isotype control. Inset numbers represent the percentage of GATA3-positive cells. (b and c) Western blot analysis of nuclear levels of GATA3, Stat6, RelA, c-Maf, and NFATc1 in cell cultures as above (b) or in Th2 cells stimulated with anti-CD3 plus anti-CD28 (c). Anti-proliferating cell nuclear antigen was used as a loading control in b and c. The results are representative of three independent experiments.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Based on these observations and the impairment of Th2 differentiation<SUP> </SUP>and function of PKC
zeta.gif
<SUP>?/?</SUP> T cells, we considered it<SUP> </SUP>important to determine whether PKC
zeta.gif
is activated in Th2 cells<SUP> </SUP>upon T cell receptor (TCR) activation. Thus, CD4<SUP>+</SUP> T cells polarized<SUP> </SUP>under Th2 conditions were incubated with anti-CD3, and, afterward,<SUP> </SUP>PKC
zeta.gif
enzymatic activity was determined as above. The incubation<SUP> </SUP>with anti-CD3 triggers a dramatic increase in PKC
zeta.gif
activity (Fig.<SUP> </SUP>3c) without appreciable changes in the levels of the enzyme<SUP> </SUP>(Fig. 3c). Collectively, these results indicate that PKC
zeta.gif
is<SUP> </SUP>activated when Th2-polarized CD4<SUP>+</SUP> T cells are rechallenged with<SUP> </SUP>anti-CD3. Th differentiation is modulated by signals emanating<SUP> </SUP>from the TCR and the cytokines generated during this polarization<SUP> </SUP>process, particularly IL-4, which is present in the culture<SUP> </SUP>medium of CD4<SUP>+</SUP> T cells induced to differentiate to the Th2 lineage.<SUP> </SUP>Importantly, IL-4 is synthesized by Th2 cells when rechallenged<SUP> </SUP>with an anti-CD3 antibody in the absence of any exogenous cytokine,<SUP> </SUP>which exerts a positive feedback activation loop (11). To determine<SUP> </SUP>whether PKC
zeta.gif
activation in CD3-triggered CD4<SUP>+</SUP> T cells polarized<SUP> </SUP>under Th2 conditions is a direct effect of TCR signaling or<SUP> </SUP>whether it is mediated by the secreted IL-4, WT CD4<SUP>+</SUP> Th2 cells<SUP> </SUP>activated with anti-CD3 were incubated in the presence of either<SUP> </SUP>neutralizing anti-IL-4 or anti-IL-5 antibodies, after which,<SUP> </SUP>PKC
zeta.gif
activity was determined as above. According to the results<SUP> </SUP>of Fig. 3c, PKC
zeta.gif
activation by anti-CD3 is dramatically inhibited<SUP> </SUP>by the presence of anti-IL-4 but not by the presence of anti-IL-5<SUP> </SUP>(Fig. 3c). These results indicate that IL-4 is responsible for<SUP> </SUP>the activation of PKC
zeta.gif
in CD3-restimulated Th2 cells and that<SUP> </SUP>PKC
zeta.gif
could be part of the IL-4 signaling machinery but that it<SUP> </SUP>is not a direct step in the TCR signal transduction cascade.<SUP> </SUP>To address this point, na?ve CD4<SUP>+</SUP> T cells were incubated<SUP> </SUP>with IL-4 for different times, and PKC
zeta.gif
enzymatic activity was<SUP> </SUP>determined as above. Interestingly, the addition of IL-4 provokes<SUP> </SUP>a reproducible and robust activation of PKC
zeta.gif
in these cells (Fig.<SUP> </SUP>3d), demonstrating that PKC
zeta.gif
constitutes a potentially important<SUP> </SUP>step in IL-4 signaling. If this model is correct, that would<SUP> </SUP>imply that the activation of signaling cascades of the TCR should<SUP> </SUP>not be impaired in the PKC
zeta.gif
<SUP>?/?</SUP> na?ve CD4<SUP>+</SUP> T<SUP> </SUP>cells but that the stimulation of the IL-4 pathway should be<SUP> </SUP>inhibited. To address this point, we incubated na?ve WT<SUP> </SUP>and PKC
zeta.gif
<SUP>?/?</SUP> CD4<SUP>+</SUP> T cells with or without IL-4, after<SUP> </SUP>which, tyrosine phosphorylation of Stat6 and Jak1 was determined<SUP> </SUP>by immunoblotting with phospho-site-specific antibodies. Results<SUP> </SUP>in Fig. 3e Left demonstrate that the loss of PKC
zeta.gif
dramatically<SUP> </SUP>impairs the activation of Stat6 and Jak1 in na?ve CD4<SUP>+</SUP><SUP> </SUP>T cells. However, the loss of PKC
zeta.gif
does not affect the activation<SUP> </SUP>of ERK or NFATc1 (Fig. 3f) or that of NF-
kappa.gif
B (Fig. 3g) or I
kappa.gif
B kinase<SUP> </SUP>activity (Fig. 3h) in these cells when stimulated with anti-CD3<SUP> </SUP>plus anti-CD28. The secretion of IL-4 and IL-5 in na?ve<SUP> </SUP>CD4<SUP>+</SUP> T cells activated with anti-CD3 is normal in the PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>cells (Fig. 3i), reinforcing the notion that PKC
zeta.gif
is not a direct<SUP> </SUP>target of TCR signaling. Likewise, the loss of PKC
zeta.gif
did not affect<SUP> </SUP>IL-2-induced Stat5 activation in this system (Fig. 3e Right).<SUP> </SUP>Taken together, these results suggest that the defect in Th2-polarized<SUP> </SUP>cells is accounted for by the important role played by PKC
zeta.gif
in<SUP> </SUP>IL-4 signaling but not in TCR downstream events. This model<SUP> </SUP>is consistent with our previously published results that demonstrated<SUP> </SUP>the lack of defects in the proliferation of na?ve T cells<SUP> </SUP>from PKC
zeta.gif
<SUP>?/?</SUP> mice, a phenomenon that is clearly dependent<SUP> </SUP>on IL-2 production and signaling (8). In contrast, because the<SUP> </SUP>common
gamma.gif
-chain receptor is essential for IL-2 and IL-4 function,<SUP> </SUP>the fact that IL-2 signaling is intact in the PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>mice (Fig. 3e Right) indicates that the defects observed in<SUP> </SUP>the IL-4 pathway cannot be explained by potential alterations<SUP> </SUP>in the levels of this receptor subunit. In addition, the data<SUP> </SUP>in Fig. 7, which is published as supporting information on the<SUP> </SUP>PNAS web site, demonstrate that the levels of the
alpha.gif
-chain of<SUP> </SUP>the IL-4 receptor are intact in na?ve and Th2-polarized<SUP> </SUP>T cells as demonstrated by FACS analysis to detect surface expression<SUP> </SUP>of the receptor (Fig. 1a) and immunoblotting (Fig. 1b). Interestingly,<SUP> </SUP>the nuclear translocation of activated Stat6 is dramatically<SUP> </SUP>inhibited in the PKC
zeta.gif
<SUP>?/?</SUP> Th2 cells (Fig. 4a), and<SUP> </SUP>the exogenous addition of IL-4 does not bypass this blockade<SUP> </SUP>(Fig. 4b). These results are consistent with the notion that<SUP> </SUP>PKC
zeta.gif
is required for the efficient activation of Jak1 and the<SUP> </SUP>subsequent phosphorylation and nuclear translocation of Stat6.<SUP> </SUP>
<SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (35K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 3. Biochemical signaling pathways in PKC
zeta.gif
<SUP>?/?</SUP> cells. (a) Western blot analysis of PKC
zeta.gif
and PKC
lambda.gif
/
iota.gif
in lung from WT and PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice. (b) Extracts from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 polarizing conditions were analyzed by immunoblotting for PKC
zeta.gif
, GATA3, and T-bet expression and by PKC
zeta.gif
kinase activity (KA). (c) WT Th2-polarized T cells were incubated with or without anti-CD3 in the presence or absence of neutralizing anti-IL-4 or anti-IL-5 antibodies, and PKC
zeta.gif
kinase activity (KA) and PKC
zeta.gif
levels were determined. (d) PKC
zeta.gif
kinase activity (KA) and PKC
zeta.gif
levels were measured in Th2-polarized cells stimulated with IL-4 for different times. (e) Na?ve CD4<SUP>+</SUP> T cells were stimulated or not stimulated with IL-4 or IL-2 for 10 min; afterward, phospho-Stat6, phospho-Jak1, and phospho-Stat5 levels, as well as levels of Stat6, Jak1, and Stat5, were determined by immunoblotting. (f) Western blot analysis of phospho-ERK, ERK, and NFATc1 in na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (g) NF-
kappa.gif
B activation was analyzed by EMSA in nuclear extracts prepared from na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (h) I
kappa.gif
B kinase activity was determined in the above extracts. The results are representative of three independent experiments. (i) Cytokine production of IL-4 and IL-5 analyzed by ELISA in na?ve CD4<SUP>+</SUP> T cells, either WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO), stimulated with anti-CD3 plus anti-CD28. The results are the mean ? SD of three independent experiments with incubations in triplicate.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Loss of PKC
zeta.gif
Inhibits Allergic Airway Disease.
It is well established<SUP> </SUP>that the Th2 immune response is responsible of the development<SUP> </SUP>of allergic airway inflammation (12?15). Because the loss<SUP> </SUP>of PKC
zeta.gif
results in impaired Th2 activation, we reasoned that<SUP> </SUP>PKC
zeta.gif
<SUP>?/?</SUP> mice would display reduced inflammatory response<SUP> </SUP>in a model of OVA-induced allergic airway disease that predominantly<SUP> </SUP>generates a Th2 response. Therefore, mice that are either WT<SUP> </SUP>or PKC
zeta.gif
<SUP>?/?</SUP> were sensitized to OVA and then challenged<SUP> </SUP>twice with aerosolized antigen or PBS on the same day. Forty-eight<SUP> </SUP>hours after the aerosol challenge, mice were killed, the lungs<SUP> </SUP>were examined histologically by hematoxylin/eosin (H&E)<SUP> </SUP>staining for eosinophilic infiltration, and BAL was performed<SUP> </SUP>to determine inflammatory cell recruitment. There was a robust<SUP> </SUP>increase in total BAL cell numbers in WT mice that were OVA<SUP> </SUP>sensitized and challenged with aerosolized antigen compared<SUP> </SUP>with PBS-challenged mice (Fig. 5a Left), due especially to eosinophils<SUP> </SUP>(Fig. 5a Right). However, this increase was dramatically reduced<SUP> </SUP>in the PKC
zeta.gif
<SUP>?/?</SUP> mice (Fig. 5a), indicating that the<SUP> </SUP>impairment in the Th2 response observed in these mutant mice<SUP> </SUP>inhibits airway inflammation. Consistent with this notion, H&E<SUP> </SUP>histological analysis of lung sections from this experiment<SUP> </SUP>shows that whereas the challenged WT mice display a prominent<SUP> </SUP>inflammatory response with massive perivascular and peribronchial<SUP> </SUP>infiltration with abundant eosinophils, PKC
zeta.gif
<SUP>?/?</SUP> mice<SUP> </SUP>display a much more attenuated response (Fig. 5b). CD11b staining<SUP> </SUP>confirms a dramatic reduction in granulocyte infiltration in<SUP> </SUP>the OVA-challenged PKC
zeta.gif
<SUP>?/?</SUP> mice (Fig. 5c). The production<SUP> </SUP>of mucus in asthmatic patients is severely debilitating and<SUP> </SUP>may lead to death. Periodic acid Schiff's base staining of lung<SUP> </SUP>sections consistently showed mucus production in the airway<SUP> </SUP>epithelium and alveoli of WT mice. In contrast, and concurring<SUP> </SUP>with the milder allergic response to the OVA challenge observed<SUP> </SUP>in the PKC
zeta.gif
<SUP>?/?</SUP> mice, mucus production was not observed<SUP> </SUP>in lung sections from these animals (data not shown). In addition,<SUP> </SUP>BAL IL-4, IL-5, IL-13, and eotaxin (Fig. 5d) supernatant levels,<SUP> </SUP>which were dramatically increased in OVA-challenged WT mice,<SUP> </SUP>were severely reduced in similarly treated PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>mice.<SUP> </SUP>
<SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (39K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 4. PKC
zeta.gif
is required for Stat6 nuclear translocation. Th2 polarized WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) cells were restimulated or left unstimulated with anti-CD3 or anti-CD3 plus anti-CD28 in the absence (a) or presence (b) of IL-4, and nuclear translocation of Stat6 was determined by confocal analysis. Stat6 (green) or TO-PRO nuclear (blue) staining was visualized. The results are representative of three independent experiments.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER><SUP></SUP>
<!-- null -->
<CENTER><TABLE cellSpacing=0 cellPadding=0 width="95%"><TBODY><TR bgColor=#e1e1e1><TD><TABLE cellSpacing=2 cellPadding=2><TBODY><TR bgColor=#e1e1e1><TD vAlign=top align=middle bgColor=#ffffff>
View larger version (38K):
<NOBR>[in this window]
[in a new window]
</NOBR> </TD><TD vAlign=top align=left>Fig. 5. Role of PKC
zeta.gif
in OVA-induced allergic airway disease. (a?d) OVA-induced allergic airway inflammation is impaired in PKC
zeta.gif
<SUP>?/?</SUP> mice. Total cell numbers and eosinophils in BAL fluids were determined (a). Lung sections were prepared and stained with H&E (b) or with anti-CD11b (c). Levels of IL-4, IL-5, IL-13, and eotaxin in the BAL fluids were measured by ELISA (d). (e) Adoptively transferred Th2 WT into PKC
zeta.gif
<SUP>?/?</SUP> (KO) cells can generate airway inflammation. Th2 WT and PKC
zeta.gif
<SUP>?/?</SUP> (KO) cells were generated by using mice sensitized with OVA and alum. Th2 cells were collected and injected into either WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) recipient mice. The mice were exposed to aerosolized OVA, and lungs were prepared for histology and stained with H&E. Data shown are representative of two experiments that each time involved six WT and six PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice. a and d are the mean ? SD; n = 6 for each genotype. **, P < 0.01; ***, P < 0.001.
</TD></TR></TBODY></TABLE></TD></TR></TBODY></TABLE></CENTER>Adoptive Transfer Experiments Support a Critical Role of PKC
zeta.gif
<SUP> </SUP>in Th2 Function.
The results from the asthma model experiments<SUP> </SUP>are consistent with a critical role of PKC
zeta.gif
in Th2 function.<SUP> </SUP>However, it would be of great interest to determine whether<SUP> </SUP>this phenotype is mostly due to defects in Th2 cells or whether<SUP> </SUP>the loss of PKC
zeta.gif
in the lung resident cells might contribute<SUP> </SUP>to the inhibition in allergic airway inflammation observed in<SUP> </SUP>the PKC
zeta.gif
mutant mice. To address this question, we transferred<SUP> </SUP>in vitro-generated WT and PKC
zeta.gif
<SUP>?/?</SUP> Th2 cells into<SUP> </SUP>PKC
zeta.gif
<SUP>?/?</SUP> mice and determined the sensitivity of these<SUP> </SUP>mice to the asthma model. Following a previously established<SUP> </SUP>method (16), we induced Th2 cells by i.p. injections of WT and<SUP> </SUP>PKC
zeta.gif
<SUP>?/?</SUP> mice with OVA, and, after 5 days of immunization,<SUP> </SUP>CD4<SUP>+</SUP> T cells from spleens and lymph nodes were isolated and<SUP> </SUP>subsequently cultured with antigen-presenting cells, OVA, and<SUP> </SUP>IL-4 for 4 days. Afterward, Th2-polarized cells were i.v. injected<SUP> </SUP>in equal numbers into WT and PKC
zeta.gif
<SUP>?/?</SUP> mice, whereas<SUP> </SUP>some control WT and PKC
zeta.gif
<SUP>?/?</SUP> mice did not receive<SUP> </SUP>cells. Mice were then challenged with inhaled OVA as described<SUP> </SUP>in Materials and Methods. Twenty-four hours after the final<SUP> </SUP>challenge, mice were killed, and lung inflammation was analyzed<SUP> </SUP>histologically by H&E staining as above. Importantly, H&E<SUP> </SUP>histological analysis of lung sections from this experiment<SUP> </SUP>shows that whereas the challenged PKC
zeta.gif
<SUP>?/?</SUP> mice that<SUP> </SUP>have been injected with PKC
zeta.gif
<SUP>?/?</SUP> Th2 cells showed<SUP> </SUP>little or no inflammation, the mutant mice injected with WT<SUP> </SUP>Th2 cells displayed a prominent inflammatory response with massive<SUP> </SUP>perivascular and peribronchial infiltration (Fig. 5e). In contrast,<SUP> </SUP>the WT control mice that were not challenged showed no inflammation<SUP> </SUP>at all (Fig. 5e). Also, the injection of PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>Th2 cells into WT mice did not produce significant inflammation<SUP> </SUP>(Fig. 5e). These results suggest that the loss of PKC
zeta.gif
in the<SUP> </SUP>lung resident cells does not contribute in a significant manner<SUP> </SUP>to the OVA-induced airway inflammatory response and demonstrate<SUP> </SUP>the critical role of PKC
zeta.gif
in Th2 function in vivo.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Discussion [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]Top
Abstract
Materials and Methods
Results
dot.gif
Discussion
References
[/SIZE]</TH></TR></TBODY></TABLE>
The understanding of the signaling cascades that regulate asthma,<SUP> </SUP>and Th2 polarization in particular, is an important issue in<SUP> </SUP>immunology. Because Th2 cells are critical players in the orchestration<SUP> </SUP>of the networks activated during allergic airway inflammation,<SUP> </SUP>these signaling pathways are a rich source of therapeutic targets<SUP> </SUP>in asthma and possibly other allergic diseases. The fact that<SUP> </SUP>PKC
zeta.gif
is a critical modulator of the Th2 response strongly suggests<SUP> </SUP>that it is a potentially relevant target for these pathological<SUP> </SUP>alterations of the immune system. Our data indicate that the<SUP> </SUP>loss of PKC
zeta.gif
leads to a clear impairment in the secretion of<SUP> </SUP>Th2 cytokines in ex vivo and in vivo experiments due to the<SUP> </SUP>inability of the PKC
zeta.gif
<SUP>?/?</SUP> CD4<SUP>+</SUP> T cells to differentiate<SUP> </SUP>adequately along the Th2 lineage. Thus, the loss of PKC
zeta.gif
results<SUP> </SUP>in the generation of Th2 cells in ex vivo cultures that poorly<SUP> </SUP>activate GATA3, c-Maf, Stat6, and NFATc1 during the Th2 differentiation<SUP> </SUP>program. Also, RelA activation is impaired in the PKC
zeta.gif
<SUP>?/?</SUP><SUP> </SUP>cells. Although PKC
zeta.gif
has been shown to be involved in NF-
kappa.gif
B nuclear<SUP> </SUP>translocation and I
kappa.gif
B kinase activation in lung (7) and liver<SUP> </SUP>(17), we think that the defect observed in RelA activation,<SUP> </SUP>and in the other transcription factors, in Th2-polarized cells<SUP> </SUP>is secondary to an impaired differentiation program in the mutant<SUP> </SUP>cells due to the essential role played by PKC
zeta.gif
in IL-4 signaling.<SUP> </SUP>In this regard, Th2 differentiation in vitro is triggered by<SUP> </SUP>TCR activation and the IL-4 present in the culture medium. Notably,<SUP> </SUP>the activation of PKC
zeta.gif
in anti-CD3-rechallenged Th2 cells requires<SUP> </SUP>the autocrinely secreted IL-4, suggesting that PKC
zeta.gif
is not a<SUP> </SUP>direct downstream target of the TCR pathway but is a critical<SUP> </SUP>mediator of IL-4 signal transduction. Consistent with this model,<SUP> </SUP>IL-4 is sufficient to activate PKC
zeta.gif
in na?ve T cells, and<SUP> </SUP>the loss of this kinase impairs Jak1/Stat6 activation by IL-4<SUP> </SUP>in these cells, whereas it is dispensable for the activation<SUP> </SUP>of TCR proximal signals such as ERK and NF-
kappa.gif
B activation. Therefore,<SUP> </SUP>the results presented here establish PKC
zeta.gif
as a critical player<SUP> </SUP>in the Th2 differentiation programs downstream the IL-4 receptor<SUP> </SUP>and independently from TCR-activated signals. The data are consistent<SUP> </SUP>with our previously published results that demonstrated that<SUP> </SUP>PKC
zeta.gif
is not involved in TCR-driven activation of na?ve T<SUP> </SUP>cell proliferation and IL-2 production (8). Interestingly, the<SUP> </SUP>loss of PKC
zeta.gif
leads to impaired Stat6 tyrosine phosphorylation<SUP> </SUP>and nuclear translocation due to the fact that PKC
zeta.gif
is required<SUP> </SUP>for the proper stimulation of Jak1. Our previous results indicated<SUP> </SUP>that PKC
zeta.gif
interacts with and phosphorylates Jak1 in vitro and<SUP> </SUP>in IL-4 activated cells (17), which offers a mechanistic explanation<SUP> </SUP>to the Th2 inflammatory phenotype of the PKC
zeta.gif
mutant mice reported<SUP> </SUP>here.<SUP> </SUP>
Particularly relevant from the point of view of lung inflammatory<SUP> </SUP>pathologies are our results from the OVA-induced allergic airway<SUP> </SUP>disease model. These data validate PKC
zeta.gif
in asthma, because the<SUP> </SUP>mutant mice show a dramatically reduced response to OVA-induced<SUP> </SUP>airway inflammation. This response is the consequence of a complex<SUP> </SUP>set of cellular interactions involving the recruited Th2 lymphocytes<SUP> </SUP>and lung resident cells (1, 11). Of note, adoptive transfer<SUP> </SUP>experiments reported in this study demonstrate that the loss<SUP> </SUP>of PKC
zeta.gif
in lung resident cells does not contribute significantly<SUP> </SUP>to the impairment of the inflammatory response in this system,<SUP> </SUP>whereas the loss of PKC
zeta.gif
in Th2 cells is of great importance.<SUP> </SUP>These data reinforce the notion that PKC
zeta.gif
is required for Th2<SUP> </SUP>function due to its critical role in IL-4 signaling. Our results<SUP> </SUP>also explain previous observations that PKC
zeta.gif
<SUP>?/?</SUP> mice<SUP> </SUP>have defects in mounting an optimal adaptive immune response<SUP> </SUP>to a T-dependent antigen without a defect in na?ve T cell<SUP> </SUP>activation (8). Thus, our system is different from the PKC
theta.gif
<SUP>?/?</SUP><SUP> </SUP>mice. In contrast to the PKC
zeta.gif
<SUP>?/?</SUP> mice, which have<SUP> </SUP>a defect in Th2 cells but not in na?ve T cell proliferation<SUP> </SUP>(8), in the case of the PKC
theta.gif
<SUP>?/?</SUP> mice, the alterations<SUP> </SUP>were not restricted to the Th2 differentiation program (18?20);<SUP> </SUP>defects were also found in NF-
kappa.gif
B activation and proliferation<SUP> </SUP>of na?ve T cells (21, 22), suggesting that the role of<SUP> </SUP>PKC
zeta.gif
is more constrained to the Th2 polarization mechanism and<SUP> </SUP>that the role of PKC
theta.gif
has a broader impact in T cell function.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Acknowledgements [/SIZE]</TH></TR></TBODY></TABLE>
This work was supported by Ministerio de Ciencia y Tecnolog?a<SUP> </SUP>Grants SAF2003-02613 (to M.T.D.-M.) and SAF2002-0187 (to J.M.)<SUP> </SUP>and by an institutional grant from Fundaci?n Ram?n<SUP> </SUP>Areces to the Centro de Biolog?a Molecular Severo Ochoa.<SUP> </SUP>J.M. is recipient of the Ayuda Investigaci?n Juan March<SUP> </SUP>2001, and P.M. is the recipient of Consejo Superior de Investigaciones<SUP> </SUP>Cientificas Grant I3P-PC2003.<SUP> </SUP>
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] Footnotes [/SIZE]</TH></TR></TBODY></TABLE>
<!-- null -->Author contributions: P.M., P.R., G.M., C.M.-A, M.T.D.-M., and<SUP> </SUP>J.M. designed research; P.M., R.V., S.R.-M., A.Z., I.S., P.R.,<SUP> </SUP>and M.T.D.-M. performed research; M.L. and J.K. contributed<SUP> </SUP>new reagents/analytic tools; J.M. analyzed data; and G.M., M.T.D.-M.,<SUP> </SUP>and J.M. wrote the paper.<SUP> </SUP>
<!-- null -->This paper was submitted directly (Track II) to the PNAS office.<SUP> </SUP>
<!-- null -->Abbreviations: Th, T helper; OVA, ovalbumin; BAL, bronchoalveolar<SUP> </SUP>lavage; ERK, extracellular signal-regulated kinase; NFAT, nuclear<SUP> </SUP>factor of activated T cells; TCR, T cell receptor; H&E,<SUP> </SUP>hematoxylin/eosin.<SUP> </SUP>
<!-- null --><SUP>?</SUP> To whom correspondence should be addressed. E-mail: jmoscat@cbm.uam.es<SCRIPT type=text/javascript><!-- var u = "jmoscat", d = "cbm.uam.es"; document.getElementById("em0").innerHTML = '<a href="mailto:' + u + '@' + d + '">' + u + '@' + d + '<\/a>'//--></SCRIPT> .
? 2005 by The National Academy of Sciences of the USA
<!-- null -->
<TABLE cellSpacing=0 cellPadding=0 width="100%" bgColor=#e1e1e1><TBODY><TR><TD vAlign=center align=left width="5%" bgColor=#ffffff>
rarrow.gif
</TD><TH vAlign=center align=left width="95%">[SIZE=+2] References [/SIZE]</TH></TR></TBODY></TABLE><TABLE cellPadding=5 align=right border=1><TBODY><TR><TH align=left>[SIZE=-1]Top
Abstract
Materials and Methods
Results
Discussion
dot.gif
References
[/SIZE]</TH></TR></TBODY></TABLE>
  1. <!-- null --><LI value=1>Luster, A. D. & Tager, A. M. (2004) Nat. Rev. Immunol. 4, 711?724.<!-- HIGHWIRE ID="102:28:9866:1" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=2>Mosmann, T. R. & Coffman, R. L. (1989) Annu. Rev. Immunol. 7, 145?173.<!-- HIGHWIRE ID="102:28:9866:2" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=3>Shuai, K. & Liu, B. (2003) Nat. Rev. Immunol. 3, 900?911.<!-- HIGHWIRE ID="102:28:9866:3" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=4>Paul, W. E. & Seder, R. A. (1994) Cell 76, 241?251.<!-- HIGHWIRE ID="102:28:9866:4" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=5>O'Shea, J. J., Gadina, M. & Schreiber, R. D. (2002) Cell 109, Suppl., S121?S131.<!-- HIGHWIRE ID="102:28:9866:5" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=6>Moscat, J., Diaz-Meco, M. T. & Rennert, P. (2003) EMBO Rep. 4, 31?36.<!-- HIGHWIRE ID="102:28:9866:6" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=7>Leitges, M., Sanz, L., Martin, P., Duran, A., Braun, U., Garcia, J. F., Camacho, F., Diaz-Meco, M. T., Rennert, P. D. & Moscat, J. (2001) Mol. Cell 8, 771?780.<!-- HIGHWIRE ID="102:28:9866:7" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=8>Martin, P., Duran, A., Minguet, S., Gaspar, M. L., Diaz-Meco, M. T., Rennert, P., Leitges, M. & Moscat, J. (2002) EMBO J. 21, 4049?4057.<!-- HIGHWIRE ID="102:28:9866:8" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=9>Chensue, S. W., Lukacs, N. W., Yang, T. Y., Shang, X., Frait, K. A., Kunkel, S. L., Kung, T., Wiekowski, M. T., Hedrick, J. A., Cook, D. N., et al. (2001) J. Exp. Med. 193, 573?584.<!-- HIGHWIRE ID="102:28:9866:9" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=10>Ho, I. C. & Glimcher, L. H. (2002) Cell 109, Suppl., S109?S120.<!-- HIGHWIRE ID="102:28:9866:10" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=11>Murphy, K. M. & Reiner, S. L. (2002) Nat. Rev. Immunol. 2, 933?944.<!-- HIGHWIRE ID="102:28:9866:11" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=12>Elias, J. A., Lee, C. G., Zheng, T., Ma, B., Homer, R. J. & Zhu, Z. (2003) J. Clin. Invest. 111, 291?297.<!-- HIGHWIRE ID="102:28:9866:12" --><NOBR>[Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=13>Pernis, A. B. & Rothman, P. B. (2002) J. Clin. Invest. 109, 1279?1283.<!-- HIGHWIRE ID="102:28:9866:13" --><NOBR>[Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=14>Ray, A. & Cohn, L. (1999) J. Clin. Invest. 104, 985?993.<!-- HIGHWIRE ID="102:28:9866:14" --><NOBR>[Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=15>Herrick, C. A. & Bottomly, K. (2003) Nat. Rev. Immunol. 3, 405?412.<!-- HIGHWIRE ID="102:28:9866:15" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=16>Das, J., Chen, C. H., Yang, L., Cohn, L., Ray, P. & Ray, A. (2001) Nat. Immunol. 2, 45?50.<!-- HIGHWIRE ID="102:28:9866:16" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=17>Duran, A., Rodriguez, A., Martin, P., Serrano, M., Flores, J. M., Leitges, M., Diaz-Meco, M. T. & Moscat, J. (2004) EMBO J. 23, 4595?4605.<!-- HIGHWIRE ID="102:28:9866:17" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=18>Marsland, B. J., Soos, T. J., Spath, G., Littman, D. R. & Kopf, M. (2004) J. Exp. Med. 200, 181?189.<!-- HIGHWIRE ID="102:28:9866:18" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=19>Cannons, J. L., Yu, L. J., Hill, B., Mijares, L. A., Dombroski, D., Nichols, K. E., Antonellis, A., Koretzky, G. A., Gardner, K. & Schwartzberg, P. L. (2004) Immunity 21, 693?706.<!-- HIGHWIRE ID="102:28:9866:19" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE --><!-- null --><LI value=20>Salek-Ardakani, S., So, T., Halteman, B. S., Altman, A. & Croft, M. (2004) J. Immunol. 173, 6440?6447.<!-- HIGHWIRE ID="102:28:9866:20" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null --> <LI value=21>Pfeifhofer, C., Kofler, K., Gruber, T., Tabrizi, N. G., Lutz, C., Maly, K., Leitges, M. & Baier, G. (2003) J. Exp. Med. 197, 1525?1535.<!-- HIGHWIRE ID="102:28:9866:21" --><NOBR>[Abstract/Free Full Text]</NOBR><!-- /HIGHWIRE --><!-- null -->
  2. Sun, Z., Arendt, C. W., Ellmeier, W., Schaeffer, E. M., Sunshine, M. J., Gandhi, L., Annes, J., Petrzilka, D., Kupfer, A., Schwartzberg, P. L. & Littman, D. R. (2000) Nature 404, 402?407.<!-- HIGHWIRE ID="102:28:9866:22" -->[CrossRef][ISI][Medline] <!-- /HIGHWIRE -->
 
Figure 1

Figure 1



Fig. 1. Role of PKC
zeta.gif
in Th2 differentiation and cytokine synthesis. (a) Secretion of IFN-
gamma.gif
in Th1 cells or IL-5, IL-4, IL-13, and IL-10 in Th2 cells in WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice stimulated with anti-CD3 was determined by ELISA. (b) IL-4 intracellular staining of Th2 cells in WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice either untreated or treated with anti-CD3 alone or in combination with anti-CD28. Inset numbers represent the percentage of IL-4-positive cells. The results in a are the mean ? SD of three independent experiments with incubations in triplicate. The results in b are representative of another two experiments. ***, P < 0.001.
 
Figure 2

Figure 2



Fig. 2. Th2 transcription factors in PKC
zeta.gif
<SUP>?/?</SUP> cells. (a) Intracellular staining of GATA3 in Th0, Th1, and Th2 cells in WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice. The solid line represents GATA3 staining; the dashed line corresponds to the mouse IgG1 isotype control. Inset numbers represent the percentage of GATA3-positive cells. (b and c) Western blot analysis of nuclear levels of GATA3, Stat6, RelA, c-Maf, and NFATc1 in cell cultures as above (b) or in Th2 cells stimulated with anti-CD3 plus anti-CD28 (c). Anti-proliferating cell nuclear antigen was used as a loading control in b and c. The results are representative of three independent experiments.
 
Figure 3

Figure 3

zpq0270587380003.jpeg




Fig. 3. Biochemical signaling pathways in PKC
zeta.gif
<SUP>?/?</SUP> cells. (a) Western blot analysis of PKC
zeta.gif
and PKC
lambda.gif
/
iota.gif
in lung from WT and PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice. (b) Extracts from CD4<SUP>+</SUP> T cells incubated under Th0, Th1, or Th2 polarizing conditions were analyzed by immunoblotting for PKC
zeta.gif
, GATA3, and T-bet expression and by PKC
zeta.gif
kinase activity (KA). (c) WT Th2-polarized T cells were incubated with or without anti-CD3 in the presence or absence of neutralizing anti-IL-4 or anti-IL-5 antibodies, and PKC
zeta.gif
kinase activity (KA) and PKC
zeta.gif
levels were determined. (d) PKC
zeta.gif
kinase activity (KA) and PKC
zeta.gif
levels were measured in Th2-polarized cells stimulated with IL-4 for different times. (e) Na?ve CD4<SUP>+</SUP> T cells were stimulated or not stimulated with IL-4 or IL-2 for 10 min; afterward, phospho-Stat6, phospho-Jak1, and phospho-Stat5 levels, as well as levels of Stat6, Jak1, and Stat5, were determined by immunoblotting. (f) Western blot analysis of phospho-ERK, ERK, and NFATc1 in na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (g) NF-
kappa.gif
B activation was analyzed by EMSA in nuclear extracts prepared from na?ve CD4<SUP>+</SUP> T cells stimulated with anti-CD3 plus anti-CD28. (h) I
kappa.gif
B kinase activity was determined in the above extracts. The results are representative of three independent experiments. (i) Cytokine production of IL-4 and IL-5 analyzed by ELISA in na?ve CD4<SUP>+</SUP> T cells, either WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO), stimulated with anti-CD3 plus anti-CD28. The results are the mean ? SD of three independent experiments with incubations in triplicate.
 
Figure 4

Figure 4



Fig. 4. PKC
zeta.gif
is required for Stat6 nuclear translocation. Th2 polarized WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) cells were restimulated or left unstimulated with anti-CD3 or anti-CD3 plus anti-CD28 in the absence (a) or presence (b) of IL-4, and nuclear translocation of Stat6 was determined by confocal analysis. Stat6 (green) or TO-PRO nuclear (blue) staining was visualized. The results are representative of three independent experiments.
 
Figure 5

Figure 5

zpq0270587380005.jpeg



Fig. 5. Role of PKC
zeta.gif
in OVA-induced allergic airway disease. (a?d) OVA-induced allergic airway inflammation is impaired in PKC
zeta.gif
<SUP>?/?</SUP> mice. Total cell numbers and eosinophils in BAL fluids were determined (a). Lung sections were prepared and stained with H&E (b) or with anti-CD11b (c). Levels of IL-4, IL-5, IL-13, and eotaxin in the BAL fluids were measured by ELISA (d). (e) Adoptively transferred Th2 WT into PKC
zeta.gif
<SUP>?/?</SUP> (KO) cells can generate airway inflammation. Th2 WT and PKC
zeta.gif
<SUP>?/?</SUP> (KO) cells were generated by using mice sensitized with OVA and alum. Th2 cells were collected and injected into either WT or PKC
zeta.gif
<SUP>?/?</SUP> (KO) recipient mice. The mice were exposed to aerosolized OVA, and lungs were prepared for histology and stained with H&E. Data shown are representative of two experiments that each time involved six WT and six PKC
zeta.gif
<SUP>?/?</SUP> (KO) mice. a and d are the mean ? SD; n = 6 for each genotype. **, P < 0.01; ***, P < 0.001.
 
Back
Top